FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.
Compounds resembling key metabolites can compete with them or disrupt their use, or get incorporated into biological macromolecules, creating faulty structures that hinder cell growth and can be lethal.
Brenig Therapeutics Reveals Enhanced Safety Metrics for its LRRK2 Blocker BT-0267 Featuring Notable CSF-to-Blood Concentration at the Parkinson's Disease Symposium.
The prominent science and technology corporation, Merck, has declared a formal licensing contract with the Shanghai-based firm Abbisko Therapeutics Co. Ltd.
In biology, a sense strand or coding strand is the part of the double-stranded DNA that carries the translatable code, running in the 5' to 3' direction.
Ascletis Pharma Inc. has declared the commencement of a pivotal Phase III clinical study for its fatty acid synthase inhibitor, ASC40 (Denifanstat) , aimed at addressing the therapeutic needs of individuals with moderate to severe acne vulgaris.
UCB has received the green light from European regulators to market ZILBRYSQ[®] (zilucoplan) as a therapeutic option for generalized Myasthenia Gravis in adult patients.